Product: MCP1 Antibody
Catalog: DF7577
Source: Rabbit
Application: WB, IHC, IF/ICC, ELISA(peptide)
Reactivity: Human, Mouse, Rat
Prediction: Horse
Mol.Wt.: 14 kD; 11kD(Calculated).
Uniprot: P13500
RRID: AB_2841069

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Horse(83%)
Clonality:
Polyclonal
Specificity:
MCP1 Antibody detects endogenous levels of total MCP1.
RRID:
AB_2841069
Cite Format: Affinity Biosciences Cat# DF7577, RRID:AB_2841069.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

C-C motif chemokine 2; CCL2; CCL2_HUMAN; Chemokine (C C motif) ligand 2; GDCF 2; GDCF-2; GDCF2; HC11; HSMCR30; JE; MCAF; MCP 1; MCP-1; MCP1; MGC9434; Monocyte chemoattractant protein 1; Monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; SCYA2; Small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig je); Small inducible cytokine A2; Small inducible cytokine subfamily A (Cys Cys), member 2; Small-inducible cytokine A2; SMC CF; SMC-CF; SMCCF;

Immunogens

Immunogen:

A synthesized peptide derived from human MCP1, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Expression:
P13500 CCL2_HUMAN:

Expressed in the seminal plasma, endometrial fluid and follicular fluid (at protein level) (PubMed:23765988). Expressed in monocytes (PubMed:2513477).

Sequence:
MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
83
Pig
0
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Acts as a ligand for C-C chemokine receptor CCR2. Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions. Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.

PTMs:

Processing at the N-terminus can regulate receptor and target cell selectivity. Deletion of the N-terminal residue converts it from an activator of basophil to an eosinophil chemoattractant.

N-Glycosylated.

Subcellular Location:

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the seminal plasma, endometrial fluid and follicular fluid (at protein level). Expressed in monocytes.

Subunit Structure:

Monomer or homodimer; in equilibrium. Is tethered on endothelial cells by glycosaminoglycan (GAG) side chains of proteoglycans.

Family&Domains:

Belongs to the intercrine beta (chemokine CC) family.

Research Fields

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

References

1). Liu W et al. Micheliolide Ameliorates Diabetic Kidney Disease by Inhibiting Mtdh-mediated Renal Inflammation in Type 2 Diabetic db/db Mice. Pharmacol Res 2019 Oct 24:104506 (PubMed: 31669149) [IF=10.334]

2). Chen Y et al. Inhibition of miR-155-5p Exerts Anti-Fibrotic Effects in Silicotic Rats by Regulating Meprin α. Mol Ther Nucleic Acids 2020 Mar 6;19:350-360. (PubMed: 31877411) [IF=10.183]

Application: WB    Species: Rat    Sample: RAW264.7 cells

Figure 4. miR-155-5p Negatively Regulates Mep1a (A) Protein expression of meprin a, pro-COL I, TGF-b1, a-SMA, and MCP-1 was detected by western blotting and quantified. (B) Levels of miR-155-5p and Mep1a in rat lungs. Data are presented as the mean ± SD. n = 5 per group. (C and D) Protein (C) and (D) mRNA (D) levels of meprin a in RAW264.7 cells treated with agomiR-155-5p or antamiR-155-5p. (E) Luciferase reporter assay demonstrating Mep1a was a target of miR-155-5p. Data are presented as the mean ± SD. n = 3 per group

3). Zhao M et al. HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cell Mol Biol Lett 2021 Sep 3;26(1):40. (PubMed: 34479471) [IF=8.702]

Application: WB    Species: human    Sample: HUVECs

Fig. 3 | Efects of inhibition of HIF-1α on expression of infammation after hyperglycemic and hypoxia.b Cells were treated with KC7F2 (10 µM) or si-HIF-1α for 48 h following combined stimulation, and IL-6, IL-8, ICAM-1, MCP-1, and c HIF-1α levels were analyzed. The relative density of IL-6, IL-8,ICAM-1, and MCP-1 (d) was normalized according to GAPDH expression.

Application: WB    Species: Human    Sample: HUVECs

Fig. 3 Effects of inhibition of HIF-1α on expression of inflammation after hyperglycemic and hypoxia. a Cells were treated with glucose (25 mM) or with combined exposure to high glucose and hypoxia for 6, 12, 24, and 48 h. Exposure to glucose alone or combined stimulation with hypoxia significantly increased gene expression of HIF-1α. b Cells were treated with KC7F2 (10 µM) or si-HIF-1α for 48 h following combined stimulation, and IL-6, IL-8, ICAM-1, MCP-1, and c HIF-1α levels were analyzed. The relative density of IL-6, IL-8, ICAM-1, and MCP-1 (d) was normalized according to GAPDH expression. Importantly, the downregulation of HIF-1α decreased the secretion of IL-6, IL-8, ICAM-1 and MCP-1 based on ELISA and qRT-PCR assays (e–f). n = 3; *p < 0.05 and **p < 0.01 vs. DMSO. DMSO-treated cells, DMSO; HIF-1α inhibitors KC7F2 (10 µM)-treated cells, KC7F2 (10 µM); si-HIF-1α, small interfering RNA HIF-1α; HG, high glucose; HG + Hypoxia, combined stimulus with high glucose and hypoxia; NG, control

4). Lu H et al. Rosiglitazone Suppresses Renal Crystal Deposition by Ameliorating Tubular Injury Resulted from Oxidative Stress and Inflammatory Response via Promoting the Nrf2/HO-1 Pathway and Shifting Macrophage Polarization. Oxid Med Cell Longev 2021 Oct 14;2021:5527137. (PubMed: 34691355) [IF=7.310]

Application: WB    Species: Human    Sample: THP-1 cells

Figure 7 Genetic expression of macrophage-related molecules, proinflammatory cytokines, and anti-inflammatory cytokines. (a) mRNA levels in THP-1 cells stimulated with COM or ROSI (1 μM) or GW9662 (10 μM) by qRT-PCR. (b) Genetic expression determined by Western blot. COM: calcium oxalate monohydrate; ROSI: rosiglitazone. ∗p < 0.05; ∗∗p < 0.01.

Application: IHC    Species: Mouse    Sample: kidney tissues

Figure 2 ROSI decreased renal tubular injury, cell apoptosis, and proinflammatory response in the mouse model. (a) PAS staining. PAS staining denotes tubular injury (arrows). Scale bar = 50 μm. (b) Cell apoptosis in the kidneys (arrows). Scale bar = 50 μm. (c) The percentage of damaged tubules displayed in PAS staining. (d) The mean number of apoptotic cells per high-power field (×400; n = 10 fields per section) in the TUNEL assay. (e) Immunohistochemical distribution of genetic expression of PPARγ, Mps-related molecule MCP1, and proinflammatory cytokine IL-1β. Scale bar = 50 μm. (f) The proportion of the IHC-positive area. Gly: glyoxylic acid; ROSI: rosiglitazone; PAS: periodic acid–Schiff; IL-1β: interleukin-1β; MCP1: monocyte chemotactic protein-1; PPARγ: peroxisome proliferator-activated receptor γ; IHC: immunohistochemistry. ∗p < 0.05; ∗∗p < 0.01.

5). Ye JS et al. SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus. CNS Neurosci Ther 2019 Mar;25(3):355-366 (PubMed: 30296006) [IF=7.035]

6). Ye JS et al. SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus. CNS Neurosci Ther 2019 Mar;25(3):355-366 (PubMed: 30296006) [IF=7.035]

7). Ye JS et al. SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus. CNS Neurosci Ther 2019 Mar;25(3):355-366 (PubMed: 30296006) [IF=7.035]

8). Yang F et al. Karyopherin α 2 promotes proliferation, migration and invasion through activating NF-κB/p65 signaling pathways in melanoma cells. Life Sci 2020 Mar 31:117611 (PubMed: 32243925) [IF=6.780]

Application: WB    Species: Mice    Sample: melanoma cells

Fig. 4. KPNA2 activated NF-κB/p65 signaling pathway in melanoma cells. The expression of NF-κB p65, COX-2, ICAM-1, iNOS, MCP1, and p65 (nucleus) was analyzed by western blot in the KPNA2-overexpressing (A, B) or KPNA2-silenced cells (F, G). The nuclear translocation of p65 (nucleus) was detected by immunofluorescence assay in the KPNA2-overexpressing (C, D) or KPNA2-silenced cells (H, I). The NF-κB binding activity was analyzed by EMSA in the KPNA2- overexpressing (E) or KPNA2-silenced cells (J). Parental, blank control group; NC, negative control group; OV-KPNA2, KPNA2 overexpressed group; siRNA1-KPNA2, KPNA2-1 silencing group; siRNA2-KPNA2, KPNA2-2 silencing group. The results were obtained in three independent experiments. Mean values were compared by One-way ANOVA. (**p < 0.01, ***p < 0.001, ****p < 0.001).

9). Li X et al. Effect of nicotine on placental inflammation and apoptosis in preeclampsia-like model. Life Sci 2020 Aug 21;118314. (PubMed: 32835699) [IF=6.780]

Application: IF/ICC    Species: rat    Sample: Placental

Fig. 4.| Nicotine treatment alleviated LPS-induced inflammation related to MCP-1 production in placenta in experimental PE rats. (A) Placental tissue sections were stained with anti-MCP-1 by immunofluorescence. Nuclei were visualized with DAPI. White dotted lines show the placental cytotrophoblasts (CTBs) areas, the arrowheads indicate positive staining. The immunolocalization results shown in B were semi-quantified in Image J. The immunoreactivity was expressed relative to the data from the control (saline) samples.

10). Li Z et al. Melatonin therapy protects against renal injury before and after release of bilateral ureteral obstruction in rats. Life Sci 2019 May 14 (PubMed: 31100324) [IF=6.780]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.